MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$16,074K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Proceeds from issuance of term l...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Payments for early debt extingui...
Purchase of investments
Gain on lease termination
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Clinical And Development Costs
-
8,280
-
-
Preclinical Costs
-
-65
-
-
Personnel And Related Costs
-
3,175
-
-
Stockbased Compensation Expense
-
1,201
-
-
Other Research Costs
-
1,015
-
-
Total research and development expenses
26,744
-
17,645
59,351
Research and development expenses
-
13,606
-
-
Total general and administrative expenses
5,133
5,360
5,376
18,474
Impairment of long-lived assets
-
-
0
3,175
Total impairment charge
-
-
0
3,175
Total lease termination (gain) and impairment charge
238
-
-
-
Loss from operations
-18,033
-18,966
-23,021
-81,000
Interest income
1,508
1,182
573
3,391
Interest expense
285
331
383
1,219
Other expense, net
-257
188
-17
-19
Loss on debt extinguishment
-904
-
-
-
Net loss
-17,971
-17,927
-22,848
-78,847
Stock-based compensation
2,683
2,509
2,706
9,873
Depreciation and amortization
86
150
151
555
Non-cash lease costs
349
388
386
1,333
Net accretion of discounts on investments
341
199
186
1,056
Accretion of term loan discount and issuance costs
66
68
72
208
Loss on early debt extinguishment
-904
-
-
-
Gain on lease termination
2,592
-
-
-
Impairment charge
-
-
0
3,175
Loss on disposal of fixed assets
-246
-
-
-
Prepaid expenses and other current assets
-232
-697
47
-705
Other assets
-1
-306
-5,007
5,693
Accounts payable
-765
-1,210
-1,669
2,090
Payable and accrued liabilities due to related party
-
-
0
-149
Accrued expenses and other current liabilities
1,360
-3,012
-2,148
4,150
Other non-current liabilities
-315
-418
-404
-1,506
Net cash used in operating activities
-16,057
-18,648
-18,980
-65,162
Purchase of investments
5,754
124,486
5,974
45,619
Maturities of investments
12,250
19,500
17,256
117,135
Purchase of property and equipment
17
50
49
163
Proceeds from sale of property and equipment
44
-
-
-
Net cash (used in) provided by investing activities
6,523
-105,036
11,233
71,353
Proceeds from equity offering
0
150,000
-
-
Payments of issuance costs related to equity offering
150
9,477
-
-
Proceeds from atm offering, net of commissions
0
11
1,316
372
Proceeds from exercise of stock options under equity incentive plan
73
670
13
1
Proceeds from issuance of common stock under employee stock purchase plan
31
-
9
15
Proceeds from exercise of pre-funded warrants
3
3
-
-
Principal payments on finance leases
236
307
225
704
Principal payments on term loan
1,304
1,305
435
-
Payments for early debt extinguishment
8,176
-
-
-
Proceeds from issuance of term loan
10,000
-
-
-
Payments of debt issuance costs
104
-
-
-
Net cash provided by (used in) financing activities
137
139,595
678
-316
Net increase in cash, cash equivalents and restricted cash
-9,397
15,911
-7,069
5,875
Cash, cash equivalents and restricted cash at beginning of year
32,350
16,439
19,368
19,368
Cash, cash equivalents and restricted cash at end of period
22,953
-
-
-
Purchase of property and equipment in accounts payable and accrued expenses
26
-
-
-
Debt issuance costs in accounts payable and accrued expenses
193
-
-
-
Cash and cash equivalents
22,687
-
-
-
Restricted cash (included in prepaid expenses and other current assets)
66
-
-
-
Cash, cash equivalents and restricted cash at end of period
22,953
32,350
16,439
23,508
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$12,250K
Proceeds from issuance of
term loan
$10,000K
Proceeds from sale of
property and equipment
$44K
Proceeds from exercise of
stock options under...
$73K
Proceeds from issuance of
common stock under...
$31K
Proceeds from exercise of
pre-funded warrants
$3K
Net cash (used in)
provided by investing...
$6,523K
Net cash provided by
(used in) financing...
$137K
Canceled cashflow
$5,771K
Canceled cashflow
$9,970K
Net increase in
cash, cash...
-$9,397K
Canceled cashflow
$6,660K
Stock-based compensation
$2,683K
Accrued expenses and
other current...
$1,360K
Loss on early debt
extinguishment
-$904K
Non-cash lease costs
$349K
Loss on disposal of
fixed assets
-$246K
Prepaid expenses and
other current assets
-$232K
Depreciation and
amortization
$86K
Accretion of term loan
discount and issuance...
$66K
Other assets
-$1K
Purchase of investments
$5,754K
Purchase of property and
equipment
$17K
Payments for early debt
extinguishment
$8,176K
Principal payments on term
loan
$1,304K
Principal payments on
finance leases
$236K
Payments of issuance
costs related to...
$150K
Payments of debt issuance
costs
$104K
Net cash used in
operating activities
-$16,057K
Canceled cashflow
$5,927K
Interest income
$1,508K
Net loss
-$17,971K
Canceled cashflow
$1,508K
Gain on lease
termination
$2,592K
Accounts payable
-$765K
Net accretion of
discounts on investments
$341K
Other non-current
liabilities
-$315K
something is missing
$13,606K
Total lease
termination (gain) and...
$238K
Loss from operations
-$18,033K
Canceled cashflow
$13,844K
Loss on debt
extinguishment
-$904K
Interest expense
$285K
Other expense, net
-$257K
Total research and
development expenses
$26,744K
Total general and
administrative expenses
$5,133K
Buy us a coffee
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)